Sirolimus or steroid drops for active Graves eye disease
Treatments studied
Part of Eyes & vision, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This Phase 2 study compares sirolimus versus corticosteroids to treat active thyroid eye disease. It aims to see which treatment works better to calm eye inflammation and improve symptoms, without needing urgent eye surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have active thyroid eye disease from Graves’ disease and want to join the study
- Your eye disease must be “active” and moderately to severely affecting you, with a clinic score of 4 or higher
- Your active eye symptoms started within the last 9 months
- Your thyroid levels are controlled (normal, or only mild high/low thyroid blood tests)
- You do not need urgent eye surgery or radiation during the study, and you’re not planning it
- You can’t be pregnant or breastfeeding, and you must use reliable contraception during treatment and for 180 days after the last dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether targeted radiation to the eyes can help reduce the inflammation and symptoms of Graves' eye disease (also called thyroid eye disease). It is for people who have had eye symptoms for less than a year and whose eyes are still actively inflamed.
This study tests a combination of two drugs, tocilizumab and flupentixol-melitracen, in people with active, moderate-to-severe thyroid-associated eye disease (TED). It aims to see if this combination can reduce eye bulging, double vision, and anxiety symptoms.
This trial tests two different ways of giving a steroid medicine called methylprednisolone through an IV to treat thyroid eye disease (also called Graves orbitopathy), which causes bulging and inflammation of the eyes. The goal is to see which schedule works better and has fewer side effects.
This study tests whether high-dose steroid pulses (given through a vein) can help people with moderate to severe Graves' eye disease that is still active. It is for people who have not yet been treated with steroids and whose eye problems began within the past year.
This study tests an investigational drug, KHN939, for people with moderate-to-severe inactive thyroid eye disease (also called Graves' eye disease). The goal is to see if the drug can improve symptoms such as bulging eyes and double vision. Participation lasts for several months and involves regular check-ups.
This study tests a new medication called GenSci098 for people with active thyroid eye disease. It aims to reduce eye symptoms like redness, swelling, and bulging, and improve quality of life.
Hear when a new Thyroid Associated Ophthalmopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.